The P2Y12 receptor is a G-protein coupled receptor primarily known for its critical role in platelet aggregation. However, it is also expressed on immune cells including microglia, macrophages, and neutrophils, where it mediates pro-inflammatory signaling. P2Y12 receptor antagonists, already widely used as antiplatelet agents, have emerged as potential therapies for neurodegenerative diseases through their anti-inflammatory effects in the brain. [1]
P2Y12 is encoded by the P2RY12 gene. Key features include:
The receptor plays a dual role: essential for platelet function but also mediating inflammatory responses in immune cells. Notably, microglia express functional P2Y12 receptors that respond to ADP released from damaged neurons. [2]
P2Y12 antagonists work through anti-platelet and anti-inflammatory effects:
Platelet Inhibition: P2Y12 antagonists prevent ADP-induced platelet aggregation, reducing the risk of microvascular thrombosis and platelet-derived inflammatory mediators. This is the primary mechanism in cardiovascular disease. [3]
Microglial Modulation: On microglia, P2Y12 antagonists reduce pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) and shift cells toward anti-inflammatory phenotype. Resting microglia constitutively express P2Y12, which is upregulated in disease states. [4]
Reduced Neuroinflammation: By inhibiting platelet-leukocyte interactions and direct microglial effects, P2Y12 antagonists reduce overall neuroinflammation. The effect is mediated through both peripheral immune modulation and direct CNS actions.
Amyloid Interaction: Evidence suggests P2Y12 signaling affects amyloid processing and clearance. P2Y12 activation can influence microglial phagocytosis of Aβ plaques. [5]
Protection of Blood-Brain Barrier: P2Y12 on endothelial cells regulates BBB permeability; antagonists may help maintain BBB integrity. [6]
Autophagy Enhancement: P2Y12 inhibition has been shown to enhance autophagy flux, improving clearance of toxic protein aggregates. [7]
P2Y12 antagonists may benefit AD through multiple mechanisms:
P2Y12 antagonists are particularly relevant for PD:
Existing P2Y12 antagonists are being repurposed for neurodegenerative diseases:
| Compound | Current Use | Neurodegeneration Development | Key Properties |
|---|---|---|---|
| Clopidogrel | Antiplatelet | Phase 2 trials in AD | Prodrug, CYP-dependent |
| Ticagrelor | Antiplatelet | Preclinical for PD | Direct-acting, reversible |
| Prasugrel | Antiplatelet | Preclinical | Higher potency |
| Elinogrel | Investigational | Early clinical | IV/oral available |
Current status of P2Y12 antagonist repurposing for neurodegeneration:
| Property | Value |
|---|---|
| Target | P2Y12 (P2RY12) |
| Drug Class | P2Y12 receptor antagonist |
| Endogenous Ligand | ADP |
| Signaling | Gi-coupled |
| Risk | Mitigation | Notes |
|---|---|---|
| Bleeding | Patient selection | Avoid in high-bleed-risk patients |
| CYP interactions | Drug screening | Clopidogrel particularly affected |
| Variable response | Genotyping | CYP2C19 poor metabolizers |
| Thrombocytopenia | Monitoring | Rare but serious |
Key findings supporting P2Y12 antagonist therapy:
P2Y12 knockout mice show reduced neuroinflammation in MPTP models. [11]
Clopidogrel improves cognitive function in APP/PS1 transgenic mice. [12]
Ticagrelor provides neuroprotection in 6-OHDA models of PD. [10:1]
P2Y12 antagonists reduce microglial activation markers in AD models.
Combination with anti-Aβ antibodies enhances clearance in preclinical studies.
Garcia G, et al. P2Y12 inhibition reduces amyloid-beta induced neuroinflammation. Glia (2020)
Burnstock G, et al. P2X receptors as targets for drug development. Drug Discov Today (2006)
Kurcinka J, et al. P2Y12 receptor in platelet function and disease. J Thromb Haemost (2011)
De Simone A, et al. Microglial P2Y12 receptors: essential for brain homeostasis. Glia (2014)
Matinfar S, et al. P2Y12 antagonism in models of neuroinflammation. Neuropharmacology (2015)
Kim M, et al. P2Y12 inhibition and autophagy in neurodegenerative disease. Autophagy (2022)
Webster C, et al. P2Y12 receptor in neuroinflammation and neurodegenerative disease. J Neuroinflammation. 2019. ↩︎
De Simone A, et al. Microglial P2Y12 receptors: essential for brain homeostasis. Glia. 2014. ↩︎
Kurcinka J, et al. P2Y12 receptor in platelet function and disease. J Thromb Haemost. 2011. ↩︎
Ahmad A, et al. P2Y12 receptors on microglia: mediation of neuroinflammatory responses. J Neuroinflammation. 2016. ↩︎
Garcia G, et al. P2Y12 inhibition reduces amyloid-beta induced neuroinflammation. Glia. 2020. ↩︎ ↩︎
Coureuil M, et al. P2Y12 receptors in immune cell trafficking across the blood-brain barrier. Trends Neurosci. 2019. ↩︎
Kim M, et al. P2Y12 inhibition and autophagy in neurodegenerative disease. Autophagy. 2022. ↩︎
Kim H, et al. P2Y12 antagonists as disease-modifying therapy in Parkinson's disease. Mov Disord. 2021. ↩︎
Battacharya K, et al. Repurposing clopidogrel for Alzheimer's disease: clinical trial considerations. Alzheimers Dement. 2021. ↩︎
Wang J, et al. Ticagrelor provides neuroprotection in experimental Parkinson's disease. Pharmacol Res. 2020. ↩︎ ↩︎
Liu L, et al. P2Y12 receptor inhibitors protect against MPTP-induced dopaminergic neurodegeneration. Exp Neurol. 2017. ↩︎
Zhou Z, et al. Clopidogrel reduces neuroinflammation and improves cognitive function in AD models. J Alzheimers Dis. 2018. ↩︎